METHOD OF TREATING NEWLY DIAGNOSED HIGH-RISK STAGE 4 NEUROBLASTOMA IN CHILDREN OVER 18 MONTHS BASED ON INDUCTION CHEMOIMMUNOTHERAPY Russian patent published in 2025 - IPC A61K31/475 A61K31/282 A61K31/7048 A61K31/166 A61K39/395 A61K38/19 A61P35/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and can be used in treating newly diagnosed high-risk stage 4 neuroblastoma in children older than 18 months. Method includes after verification of diagnosis two courses of chemotherapy according to scheme N5 – vincristine 1.5 mg/m²/day intravenously for 1 hour on day 1, cisplatin 40 mg/m²/day intravenously by continuous infusion on days 1-4, etoposide 100 mg/m²/day intravenously by continuous infusion on days 1-4; and N6 – vincristine 1.5 mg/m²/day intravenously for 1 hour on days 1 and 8, dacarbazine 200 mg/m²/day intravenously for 1 hour on days 1-5, ifosfamide 1500 mg/m²/day intravenously for 23 hours on days 1-5, doxorubicin 30 mg/m²/day intravenously for 4 hours on days 6-7. Starting from 3rd course, patients receive 4 courses of similar chemotherapy in an alternating mode in combination with GD2-directed MAb ch14.18/CHO (dinutuximab beta) – courses N5-Q and N6-Q, dinutuximab beta is administered in dose of 10 mg/m²/day by continuous infusion for 5 days starting from 5th day in the N5-Q course and from 6th day in the N6-Q course. Stimulation of granulocytopoiesis in induction therapy courses is performed with application of granulocyte colony-stimulating factor (G-CSF). Delayed operation is performed after 4-6th courses of induction therapy, mobilization of haemopoietic stem cells (HSC) is performed after 2-5th courses.

EFFECT: use of the invention enables to achieve clinically significant responses to the induction stage of therapy with the expected profile of haematological and non-haematological toxicity, promotes their improvement by overcoming heterogeneous drug resistance due to the use of induction chemoimmunotherapy based on MAb ch14.18/CHO, capable of potentiating the cytostatic effects of chemotherapeutic preparations, without using granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2) with preservation of relatively constant time intervals between the planned courses.

1 cl